Compass Therapeutics (CMPX) Non-Current Assets (2019 - 2026)

Compass Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $9.5 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 29.8% year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at $39.9 million (up 59.36% YoY), while the FY2025 annual figure was $9.8 million, up 27.67% from the prior year.
• Non-Current Assets came in at $9.5 million for Q1 2026 at Compass Therapeutics, down from $9.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $10.5 million in Q2 2025 to a low of $2.1 million in Q2 2024.
• A 5-year average of $6.1 million and a median of $5.7 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets plunged 47.17% in 2024 and soared 408.62% in 2025, its largest moves.
• Compass Therapeutics' Non-Current Assets stood at $4.9 million in 2022, then slumped by 38.32% to $3.0 million in 2023, then jumped by 155.58% to $7.7 million in 2024, then advanced by 27.67% to $9.8 million in 2025, then retreated by 2.93% to $9.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $9.5 million, $9.8 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison